“It's something you want to be part of, to be proud of. You want to tell those important to you that you're doing something meaningful. That you helped change lives.”

Cameron Gray, Managing Director, Provention Bio

about us

Board of Directors

Jeff Bluestone, PhD

Director

Jeff Bluestone, PhD

Director

Dr. Bluestone is the president and CEO of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor in the Diabetes Center at University of California San Francisco. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He recently led the Parker Institute for Cancer Immunotherapy as founding CEO and President. He served as a member of the Blue Ribbon Panel, a panel of scientific experts, appointed by then Vice President Joe Biden, to guide the National Cancer Moonshot Initiative> Finally, was the Ludwig Professor and Director of the Ben May Institute at University of Chicago and served as a senior investigator at the National Cancer Institute of the National Institutes of Health.

Dr. Bluestone is a highly accomplished scientific researcher whose work over nearly three decades has focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved by the FDA for the treatment of metastatic melanoma.

Dr. Bluestone was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes (T1D), psoriatic arthritis, and the reversal of kidney transplant rejection.

He received his B.S. and M.S. from Rutgers University and his Ph.D. in immunology from the Weill Cornell Graduate School of Medical Science.

Chip Catlin

Director

Chip Catlin

Director

Mr. Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Mr. Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions adding substantial long term value for the company. Prior to Celldex, Mr. Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Mr. Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Mr. Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him an ideal addition to our board of directors.

Sean Doherty

Director

Sean Doherty

Director

Sean Doherty recently retired from his role as Managing Director of Bain Capital, LP, a private global investment firm which he joined in 2005 as the firm’s first general counsel. Earlier in his career he worked at Ropes & Gray LLP and was a law clerk to a federal district judge in Boston. Prior to law school, he was a Lieutenant in the U.S. Navy, in which he served on a Middle East Force frigate from 1990-94.

Sean led the design and creation of the JDRF T1D Fund and became the Fund’s first Board Chair in 2015, following more than a decade of service on the New England Chapter’s Board of Directors, including two years as its President. Sean and his wife, Suzy, have been involved with JDRF since 2002 when their son Finn was diagnosed with T1D at the age of 2. He served on the JDRF International Board and its Executive Committee from 2016 to 2019.

Sean received a J.D. magna cum laude from Harvard Law School and a B.A. magna cum laude in Government from Harvard College. He is a member of the board of trustees of Thayer Academy in Braintree, MA.

Ashleigh Palmer

Chief Executive Officer & Co-Founder

Ashleigh Palmer

Chief Executive Officer & Co-Founder

Ashleigh Palmer, co-founder of Provention and its CEO, is a life sciences industry entrepreneur and innovator with more than 30 years’ experience and expertise in corporate strategy formulation, preclinical and clinical drug evaluation and product development and commercialization. During his career, Mr. Palmer has served as CEO for multiple biopharma companies (both private and public) and has held numerous board director and chairman positions. In addition to Provention, Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry.

From 2015 through 2017, Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company he co-founded, dedicated to developing therapies for celiac disease and intestinal lymphoma. Celimmune was acquired by Amgen Inc. in November 2017.

Prior to founding Provention, Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, acquired by Mallinckrodt in 2015 for $2.3 billion.

Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Educated in the UK, Mr. Palmer received his MBA from the University of Bradford and his BSc honors in Biochemistry and Applied Molecular Biology from the University of Manchester.

Wayne Pisano

Director

Wayne Pisano

Director

Mr. Pisano joined our board of directors in April 2018. He also serves on the board of directors of Immunovaccine Inc., a biopharmaceutical company, since October 2011, and Oncolytics, Inc., a biotechnology company, since May 2013. Mr. Pisano served as president and CEO of VaxInnate, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. Mr. Pisano’s depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development make him a valuable member of our board of directors.

Nancy Wysenski

Director

Nancy Wysenski

Director

Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves as a member of the board of directors of Alkermes plc and Tetraphase Pharmaceuticals, each a publicly traded pharmaceutical company. Ms. Wysenski formerly served as a director for Dova Pharmaceuticals Inc., Reata Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. She is a founder of the Research Triangle Park chapter of the Healthcare Business Women's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association